CHP-134Homo sapiens (Human)Cancer cell line

Also known as: Children's Hospital of Philadelphia-134, CHP134, CHP_134, CHP 134

🤖 AI SummaryBased on 14 publications

Quick Overview

Human neuroblastoma cell line with MYCN amplification and chromosomal abnormalities.

Detailed Summary

CHP-134 is a human neuroblastoma cell line derived from a neuroblastoma tumor. It is characterized by the presence of MYCN amplification, a common genetic alteration associated with aggressive disease and poor prognosis. The cell line exhibits chromosomal abnormalities, including homogeneously staining regions (HSRs) and double minute chromosomes, which are frequently observed in neuroblastoma. These structural variations contribute to the genomic instability and oncogenic potential of the cell line. CHP-134 is used in research to study the molecular mechanisms underlying neuroblastoma progression and to evaluate therapeutic strategies targeting MYCN and other oncogenic drivers.

Research Applications

MYCN amplification studiesChromosomal abnormalities analysisOncogenic driver identificationTherapeutic target evaluation

Key Characteristics

MYCN amplificationHomogeneously staining regions (HSRs)Double minute chromosomesGenomic instability

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1124
Species	Homo sapiens (Human)
Tissue Source	Adrenal gland[UBERON:UBERON_0002369]

Donor Information

Age	1
Age Category	Pediatric
Sex	Male
Subtype Features	MYC_Amplified

Disease Information

Disease	Neuroblastoma
Lineage	Peripheral Nervous System
Subtype	Neuroblastoma
OncoTree Code	NBL

DepMap Information

Source Type	Sigma-Aldrich
Source ID	ACH-001338_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

9,12

D13S317

8,10,11

D16S539

D18S51

15,18

D19S433

12,13

D21S11

28,29

D2S1338

20,27

D3S1358

D5S818

11,12

D7S820

D8S1179

8,14

FGA

21,25

Penta D

Penta E

5,7

TH01

9,9.3

TPOX

vWA

18,19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.

Sci. Data 4:170033-170033(2017).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.

Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.

Transl. Oncol. 6:685-696(2013).

DOI PubMed PMC

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.

Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.

Nat. Genet. 45:12-17(2013).

DOI PubMed PMC

PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.

Int. J. Cancer 131:1556-1568(2012).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Oncogenic mutations of ALK kinase in neuroblastoma.";

Hayashi Y., Mano H., Ogawa S.

Nature 455:971-974(2008).

DOI PubMed

Identification of ALK as a major familial neuroblastoma predisposition gene.

Maris J.M.

Nature 455:930-935(2008).

DOI PubMed PMC

Mutations in PIK3CA are infrequent in neuroblastoma.";

Dam V., Morgan B.T., Mazanek P., Hogarty M.D.

BMC Cancer 6:177.1-177.10(2006).

DOI PubMed PMC

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.

Maris J.M.

Genes Chromosomes Cancer 43:390-403(2005).

DOI PubMed

PPM1D is a potential target for 17q gain in neuroblastoma.";

Sugimoto T., Inazawa J.

Cancer Res. 63:1876-1883(2003).

PubMed

Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.

Schlesinger H.R.

Cancer Genet. Cytogenet. 7:33-42(1982).

DOI PubMed

Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.

Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.

Nature 305:245-248(1983).

DOI PubMed

Neuronal properties of neuroectodermal tumors in vitro.";

Schlesinger H.R., Rorke-Adams L.B., Jamieson R., Hummeler K.

Cancer Res. 41:2573-2575(1981).

PubMed

Double minute chromosomes and the homogeneously staining regions in chromosomes of a human neuroblastoma cell line.

Balaban-Malenbaum G.B., Gilbert F.

Science 198:739-741(1977).

DOI PubMed

Establishment and characterization of human neuroblastoma cell lines.

Schlesinger H.R., Gerson J.M., Moorhead P.S., Maguire H., Hummeler K.

Cancer Res. 36:3094-3100(1976).

PubMed

Homogeneously staining regions and double minute chromosomes, prevalent cytogenetic abnormalities of human neuroblastoma cells.

Biedler J.L., Meyers M.B., Spengler B.A.

(In book chapter) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York; USA (1983).

DOI

Neuroblastoma.";

Thiele C.J.

(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999).

DOI